Vascular health, systemic inflammation and progressive reduction in kidney function; clinical determinants and impact on cardiovascular outcomes
Key result
In nondialysed CKD patients, flow-mediated dilatation (HR 0.52; 95% CI 0.37-0.73 per %) and C-reactive protein independently predicted fatal and nonfatal cardiovascular outcomes.
Why the study?
Do flow-mediated dilatation (FMD), intima-media thickness (IMT), and C-reactive protein (CRP) predict cardiovascular outcomes in nondialysed chronic kidney disease patients?
Population
304 nondialysed chronic kidney disease (CKD) patients Stages 1-5, mean age 46 ± 12 years, 158 men.
Design
Cohort
Follow-up
median 41 (range 6-46) months
Authors
Discussion
Loading...
Member takes
Implication
May inform CV risk stratification in nondialysed CKD; hypothesis-generating, needs prospective validation before guiding therapy.
Study Design
Type
Cohort (n=304)
Structured PICO
Do flow-mediated dilatation (FMD), intima-media thickness (IMT), and C-reactive protein (CRP) predict cardiovascular outcomes in nondialysed chronic kidney disease patients?
P
Population
304 nondialysed CKD patients Stages 1-5 (mean age 46 years, 48% female) followed for a median of 41 months.
O
Outcome
Cardiovascular outcomes (fatal and nonfatal)hard clinical
Main Result
Hazard Ratio: 0.52 (95% CI 0.37–0.73)
Endothelial dysfunction (measured by FMD) and inflammation (CRP) independently predict cardiovascular outcomes in nondialysed CKD patients, supporting the use of FMD over IMT for risk stratification.
Cite This Study
Yılmaz et al. (2011) conducted a cohort in Nondialysed chronic kidney disease (CKD) Stages 1-5 (n=304). Flow-mediated dilatation (FMD) and C-reactive protein (CRP) was evaluated on Cardiovascular outcomes (fatal and nonfatal) (HR 0.52, 95% CI 0.37-0.73). In nondialysed CKD patients, flow-mediated dilatation (HR 0.52; 95% CI 0.37-0.73 per %) and C-reactive protein independently predicted fatal and nonfatal cardiovascular outcomes.